AnGes (AJW) AI Stock Analysis

2 Followers

AnGes

(Frankfurt:AJW)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthAccelerating revenue indicates improving commercialization activity for AnGes and provides a stronger base from which to develop its biotechnology portfolio. If this trend persists, greater product or collaboration income could improve operating leverage and support progress toward sustainable scale.

Negative Factors

Persistent LossesPersistent operating and net losses show that the business has not yet established sustainable earnings, despite stronger revenue. Continued losses can limit internal reinvestment, increase dependence on financing, and make future performance highly dependent on successful commercialization of its pipeline.

AnGes (AJW) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 143.66M
Dividend Yield: ―
Average Volume (3M): 900
Price to Earnings (P/E): -2.8
Beta (1Y): 0.39
Revenue Growth: 22.13%
EPS Growth: 91.14%
Country: Germany
Employees: 56
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

AnGes Business Overview & Revenue Model

Company Description

AnGes, Inc., a biopharmaceutical firm headquartered in Ibaraki, Japan, and established in 1999, focuses on pioneering the research and development of gene-based medical solutions. Its primary therapeutic asset is Hepatocyte Growth Factor (HGF) Plasmi...

AnGes Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:AJW against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:4565	63Neutral	JPY 166.34B	-30.09	-8.51%	―	23.72%	12.48%
JP:4588	55Neutral	JPY 221.84B	-145.74	―	―	1748.97%	35.11%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JP:4593	49Neutral	JPY 32.26B	48.59	―	―	-47.32%	―
JP:7774	42Neutral	JPY 27.45B	-75.71	―	―	17.05%	10.47%

* Healthcare Sector Average

Performance Comparison

DE:AJW and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:AJW	AnGes	0.10	-0.26	-72.75%
JP:4565	Sosei Group Corporation	1811.00	962.00	113.31%
JP:4588	Oncolys BioPharma, Inc.	7900.00	6842.00	646.69%
JP:4593	Healios KK	241.00	-220.00	-47.72%
JP:7774	Japan Tissue Engineering Co., Ltd.	680.00	185.00	37.37%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

AnGes AI Stock Analysis